A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wang, Yun ^a   Herrstedt, Jørn ^b,c   Havsteen, Hanne ^c   DePoint Christensen, Rene ^d   Mirza, Mansoor Raza ^b   Lund, Bente ^e   Maenpaa, Johanna ^f   Kristensen, Gunnar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Carboplatin; Docetaxel; Phase II study; Recurrent platinum sensitive ovarian cancer; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT DISORDER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; EPIPHORA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GOOD CLINICAL PRACTICE; HEARING DISORDER; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SENSORY DYSFUNCTION; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA; VOMITING; AGED; CARCINOMA; CHEMICALLY INDUCED; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG SCREENING; FALLOPIAN TUBE NEOPLASMS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SOMATOSENSORY DISORDER; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; SOMATOSENSORY DISORDERS; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84965185266     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-937     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. DuBois A, Quinn M, Thigpen T, Vermorken J, Vall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla P, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt P, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, et al: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005, 16(Suppl 8):viii7-viii12.
3. Pfisterer J, Ledermann JA: Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006, 33:S12-S16.
4. Parmar MK, Ledermann JA, Colombo N, Du BA, Delaloye JF, Kristensen GB, Wheeler S, Swart M, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099-2106.
5. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200.
6. Armstrong DK: Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 7(Suppl 5):20-28.
7. Dranitsaris G, Elia-Pacitti J, Cottrell W: Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics 2004, 22:375-387.
8. Roila F, Cortesi E: Quality of life as a primary end point in oncology. Ann Oncol 2001, 12(Suppl 3):S3-S6.
9. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96:1682-1691.
10. Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H: Phase II trial of docetaxel and carboplatin in recurrent platinumsensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol 2007, 104:612-616.
11. Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM: Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol 2007, 105:358-364.
12. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB: Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000, 92:1534-1535.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
15. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
16. Arimoto T, Nakagawa S, Oda K, Kawana K, Yasugi T, Taketani Y: Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer. Med Oncol 2012, 29:1253-1254.
17. Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ: Peripheral neurotoxicity induced by docetaxel. Neurology 1996, 46:104-108.
18. Pujade-Lauraine E, Wagner U, Avall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, Du Bois A: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323-3329.
19. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001, 19:1901-1905.
20. Pfisterer J, Du BA, Wagner U, Quaas J, Blohmer JU, Wallwiener D, Hilpert F: Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol Oncol 2004, 92:949-956.
21. Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
22. Pfisterer J, Vergote I, Du BA, Eisenhauer E: Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005, 15(Suppl 1):36-41.
23. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999, 17:1141-1145.